A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Fox N C,
Honig L S,
van Dyck C H,
Gregg K M,
Bapineuzumab 201 Clinical Trial Investigators
Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.